Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Constructive evidenceCoverage 5/5 core metrics12 filing-based checks were evaluable.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- No current rule-based risk flags
12 filing-based checks were evaluable.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +8.7% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2026-03-31.
- Operating margin improved
Operating margin changed +2.7 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2026-03-31.
- Free cash flow was positive
Latest reported free cash flow was $972M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2026-03-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2026-03-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Healthcare Segment$4.21B70.9%+8.5% yoy
- Applied Sterilization Technologies$1.14B19.2%+9.6% yoy
- Life Science$589M9.9%+8.6% yoy
Members sum to the consolidated $5.94B for this period.
- Product$3.06B51.6%+6.6% yoy
- Service$2.88B48.4%+11.1% yoy
Members sum to the consolidated $5.94B for this period.
- United States$4.33B73.0%+8.1% yoy
- Otherforeignlocations$1.49B25.2%+11.1% yoy
- Ireland$109M1.8%+1.1% yoy
Members sum to the consolidated $5.94B for this period.
- Healthcare Segment$1.06B71.1%+9.0% yoy
- Applied Sterilization Technologies$287M19.2%+11.0% yoy
- Life Science$146M9.7%+6.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2026-03-31 · among 4,122 US-listed filers · 318 in Healthcare| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $5.9B | 82ndof 3,301 top third | 88thof 291 top third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 8.7% | 58thof 3,135 middle third | 50thof 277 middle third |
Gross margin gross profit ÷ revenue | 44.3% | 59thof 1,603 middle third | 30thof 212 bottom third |
Operating margin operating income ÷ revenue | 18.6% | 83rdof 2,819 top third | 90thof 280 top third |
Net margin net income ÷ revenue | 13.2% | 77thof 3,263 top third | 86thof 290 top third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | 16.4% | 78thof 2,679 top third | 86thof 261 top third |
Return on equity net income ÷ stockholders' equity (positive equity only) | 10.9% | 69thof 3,577 top third | 78thof 291 top third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 1.0% | 66thof 2,895 middle third | 79thof 272 top third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 67 days | 29thof 2,398 bottom third | 31stof 266 bottom third |
Cash conversion operating cash flow ÷ net income (net income > 0) | 1.7× | 58thof 2,183 middle third | 55thof 123 middle third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -5.3% | 54thof 3,577 middle third | 43rdof 272 middle third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2026-03-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 28 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Operating income OperatingIncomeLoss | fiscal year 2023-03-31 | $268M 10-K 2023-05-26 | $791M 10-K 2025-05-29 | +195.0% | first · latest · 3 filings carry it |
| Intangibles IntangibleAssetsNetExcludingGoodwill | balance at 2023-03-31 | $2.96B 10-K 2023-05-26 | $2.08B 10-K 2024-05-29 | -29.7% | first · latest · 5 filings carry it |
| Operating income OperatingIncomeLoss | fiscal year 2022-03-31 | $426M 10-K 2022-05-31 | $478M 10-K 2024-05-29 | +12.3% | first · latest · 3 filings carry it |
| Goodwill Goodwill | balance at 2022-03-31 | $4.4B 10-K 2022-05-31 | $3.94B 10-K 2024-05-29 | -10.6% | first · latest · 8 filings carry it |
| Gross profit GrossProfit | quarter 2022-09-30 | $532M 10-Q 2022-11-09 | $482M 10-K 2024-05-29 | -9.4% | first · latest · 3 filings carry it |
| Revenue Revenues | quarter 2022-09-30 | $1.2B 10-Q 2022-11-09 | $1.09B 10-K 2024-05-29 | -9.1% | first · latest · 3 filings carry it |
| Revenue Revenues | quarter 2022-06-30 | $1.16B 10-Q 2022-08-08 | $1.05B 10-K 2024-05-29 | -9.1% | first · latest · 3 filings carry it |
| Revenue Revenues | quarter 2022-12-31 | $1.22B 10-Q 2023-02-08 | $1.11B 10-K 2024-05-29 | -8.5% | first · latest · 3 filings carry it |
| Revenue Revenues | fiscal year 2023-03-31 | $4.96B 10-K 2023-05-26 | $4.54B 10-K 2025-05-29 | -8.5% | first · latest · 3 filings carry it |
| Gross profit GrossProfit | quarter 2022-06-30 | $518M 10-Q 2022-08-08 | $474M 10-K 2024-05-29 | -8.5% | first · latest · 3 filings carry it |
| Gross profit GrossProfit | quarter 2022-12-31 | $521M 10-Q 2023-02-08 | $478M 10-K 2024-05-29 | -8.3% | first · latest · 3 filings carry it |
| Gross profit GrossProfit | fiscal year 2023-03-31 | $2.16B 10-K 2023-05-26 | $1.98B 10-K 2025-05-29 | -8.3% | first · latest · 3 filings carry it |
| Gross profit GrossProfit | quarter 2023-09-30 | $594M 10-Q 2023-11-07 | $546M 10-Q 2024-11-07 | -8.0% | first · latest · 3 filings carry it |
| Revenue Revenues | fiscal year 2022-03-31 | $4.59B 10-K 2022-05-31 | $4.22B 10-K 2024-05-29 | -7.9% | first · latest · 3 filings carry it |
| Revenue Revenues | quarter 2023-06-30 | $1.28B 10-Q 2023-08-08 | $1.18B 10-Q 2024-08-08 | -7.9% | first · latest · 3 filings carry it |
| Revenue Revenues | quarter 2023-09-30 | $1.34B 10-Q 2023-11-07 | $1.24B 10-Q 2024-11-07 | -7.8% | first · latest · 3 filings carry it |
| Gross profit GrossProfit | quarter 2023-06-30 | $573M 10-Q 2023-08-08 | $529M 10-Q 2024-08-08 | -7.8% | first · latest · 3 filings carry it |
| Gross profit GrossProfit | quarter 2023-12-31 | $603M 10-Q 2024-02-08 | $560M 10-Q 2025-02-07 | -7.1% | first · latest · 3 filings carry it |
| Revenue Revenues | quarter 2023-12-31 | $1.4B 10-Q 2024-02-08 | $1.3B 10-Q 2025-02-07 | -7.0% | first · latest · 3 filings carry it |
| Receivables AccountsReceivableNetCurrent | balance at 2023-03-31 | $928M 10-K 2023-05-26 | $865M 10-K 2024-05-29 | -6.8% | first · latest · 5 filings carry it |
| Gross profit GrossProfit | fiscal year 2022-03-31 | $2.02B 10-K 2022-05-31 | $1.88B 10-K 2024-05-29 | -6.6% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2023-12-31 | $216M 10-Q 2024-02-08 | $226M 10-Q 2025-02-07 | +4.8% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2023-06-30 | $189M 10-Q 2023-08-08 | $198M 10-Q 2024-08-08 | +4.7% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2023-09-30 | $186M 10-Q 2023-11-07 | $192M 10-Q 2024-11-07 | +3.1% | first · latest |
| Net income NetIncomeLoss | quarter 2020-06-30 | $88.2M 10-Q 2020-08-07 | $89.6M 10-K 2022-05-31 | +1.6% | first · latest · 4 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2020-06-30 | $114M 10-Q 2020-08-07 | $116M 10-Q 2021-08-09 | +1.6% | first · latest |
| Gross profit GrossProfit | quarter 2020-06-30 | $286M 10-Q 2020-08-07 | $287M 10-K 2022-05-31 | +0.6% | first · latest · 4 filings carry it |
| Net income NetIncomeLoss | quarter 2020-03-31 | $123M 10-K 2020-05-29 | $123M 10-K 2021-05-28 | -0.6% | first · latest |
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
Not available for STE yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.